Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.
Future Oncol. 2016 Oct;12(20):2379-86. doi: 10.2217/fon-2016-0168. Epub 2016 Jun 22.
Oral squamous cell carcinomas represent a significant cancer burden worldwide. Unfortunately, chemoprevention strategies investigated to date have failed to produce an agent considered standard of care to prevent oral cancers. Nonetheless, recent advances in clinical trial design may streamline drug development in this setting. In this manuscript, we review some of these improvements, including risk prediction tools based on molecular markers that help select patients most suitable for chemoprevention. We also discuss the opportunities that novel preclinical models and modern molecular profiling techniques will bring to the prevention field in the near future, and propose a clinical trials framework that incorporates molecular prognostic factors, predictive markers and cancer biology as a roadmap to improve chemoprevention strategies for oral cancers.
口腔鳞状细胞癌在全球范围内是一个重大的癌症负担。不幸的是,迄今为止所研究的化学预防策略未能产生一种被认为是预防口腔癌的标准治疗方法的药物。尽管如此,最近临床试验设计的进展可能会简化该领域的药物开发。在本文中,我们回顾了其中的一些改进,包括基于分子标志物的风险预测工具,这些工具有助于选择最适合化学预防的患者。我们还讨论了新型临床前模型和现代分子分析技术在不久的将来为预防领域带来的机遇,并提出了一个临床试验框架,该框架将分子预后因素、预测标志物和癌症生物学结合起来,作为改善口腔癌化学预防策略的路线图。